Fintel reports that on January 8, 2025, Keybanc upgraded their outlook for Health Catalyst (NasdaqGS:HCAT) from Sector Weight to Overweight.
Analyst Price Forecast Suggests 58.33% Upside
As of December 23, 2024, the average one-year price target for Health Catalyst is $11.64/share. The forecasts range from a low of $9.09 to a high of $16.80. The average price target represents an increase of 58.33% from its latest reported closing price of $7.35 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Health Catalyst is 375MM, an increase of 24.21%. The projected annual non-GAAP EPS is 0.01.
What is the Fund Sentiment?
There are 386 funds or institutions reporting positions in Health Catalyst. This is an increase of 7 owner(s) or 1.85% in the last quarter. Average portfolio weight of all funds dedicated to HCAT is 0.13%, an increase of 43.75%. Total shares owned by institutions increased in the last three months by 6.99% to 66,611K shares. 
The put/call ratio of HCAT is 0.04, indicating a bullish outlook.
What are Other Shareholders Doing?
First Light Asset Management holds 4,296K shares representing 7.06% ownership of the company. In its prior filing, the firm reported owning 3,956K shares , representing an increase of 7.92%. The firm increased its portfolio allocation in HCAT by 31.30% over the last quarter.
PXSCX - Pax Small Cap Fund Investor Class holds 2,554K shares representing 4.20% ownership of the company. In its prior filing, the firm reported owning 2,154K shares , representing an increase of 15.66%. The firm increased its portfolio allocation in HCAT by 40.62% over the last quarter.
Impax Asset Management Group holds 2,554K shares representing 4.20% ownership of the company. In its prior filing, the firm reported owning 2,194K shares , representing an increase of 14.10%. The firm increased its portfolio allocation in HCAT by 43.43% over the last quarter.
Daventry Group holds 2,418K shares representing 3.97% ownership of the company. In its prior filing, the firm reported owning 2,247K shares , representing an increase of 7.05%. The firm increased its portfolio allocation in HCAT by 22.05% over the last quarter.
Primecap Management holds 2,404K shares representing 3.95% ownership of the company. In its prior filing, the firm reported owning 2,379K shares , representing an increase of 1.04%. The firm increased its portfolio allocation in HCAT by 30.73% over the last quarter.
Health Catalyst Background Information
(This description is provided by the company.)
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform-powered by data from more than 100 million patient records and encompassing trillions of facts-as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
